Feedback
Settings

Settings

1. WO2011104337 - HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

PermaLink
Publication Number WO/2011/104337
Publication Date 01.09.2011
International Application No. PCT/EP2011/052810
International Filing Date 25.02.2011
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
495
Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
519
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5355
Non-condensed oxazines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
06
Antihyperlipidemics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
12
of the kidneys
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C07D 495/04 (2006.01)
C07D 519/00 (2006.01)
A61K 31/519 (2006.01)
A61K 31/5355 (2006.01)
A61K 31/55 (2006.01)
A61P 3/00 (2006.01)
CPC
C07D 495/04
C07D 519/00
Applicants
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Str. 173 55216 Ingelheim Am Rhein, DE (AllExceptUS)
  • LEHMANN-LINTZ, Thorsten [DE/DE]; DE (UsOnly)
  • KLEY, Joerg [DE/DE]; DE (UsOnly)
  • REDEMANN, Norbert [DE/DE]; DE (UsOnly)
  • SAUER, Achim [DE/DE]; DE (UsOnly)
  • THOMAS, Leo [DE/DE]; DE (UsOnly)
  • WIEDENMAYER, Dieter [DE/DE]; DE (UsOnly)
  • AUSTEN, Matthias [DE/DE]; DE (UsOnly)
  • DANILEWICZ, John [GB/GB]; GB (UsOnly)
  • SCHNEIDER, Martin [DE/DE]; DE (UsOnly)
  • SCHREITER, Kay [DE/DE]; DE (UsOnly)
  • BLACK, Phillip [GB/GB]; GB (UsOnly)
  • BLACKABY, Wesley [GB/GB]; GB (UsOnly)
  • LINNEY, Ian [GB/GB]; GB (UsOnly)
Inventors
  • LEHMANN-LINTZ, Thorsten; DE
  • KLEY, Joerg; DE
  • REDEMANN, Norbert; DE
  • SAUER, Achim; DE
  • THOMAS, Leo; DE
  • WIEDENMAYER, Dieter; DE
  • AUSTEN, Matthias; DE
  • DANILEWICZ, John; GB
  • SCHNEIDER, Martin; DE
  • SCHREITER, Kay; DE
  • BLACK, Phillip; GB
  • BLACKABY, Wesley; GB
  • LINNEY, Ian; GB
Agents
  • HAMMANN, Heinz; Boehringer Ingelheim GmbH Corporate Patents Binger Str. 173 55216 Ingelheim Am Rhein, DE
Priority Data
10154925.126.02.2010EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
(FR) THIÉNOPYRIMIDINES CONTENANT UN GROUPE HÉTÉROCYCLOALKYLE POUR DES COMPOSITIONS PHARMACEUTIQUES
Abstract
(EN)
The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
(FR)
La présente invention porte sur de nouvelles compositions pharmaceutiques comprenant des composés thiénopyrimidines. De plus, la présente invention porte sur l'utilisation des composés thiénopyrimidines de l'invention pour la production de compositions pharmaceutiques pour la prophylaxie et/ou le traitement de maladies qui peuvent être influencées par l'inhibition de l'activité de kinase de Mnk1 et/ou Mnk2 (Mnk2a ou Mnk2b) et/ou de variantes de celles-ci.
Also published as
AU2011219761
BR112012021264
CA2791105
CL2012002318
CN102869669
EA201201193
EP2539346
IL221085
IN7400/DELNP/2012
JP2013520472
KR1020120130052
MX2012009409
PH1/2012/501691
PH12012501691
Latest bibliographic data on file with the International Bureau
# -